News | Radiation Therapy | February 18, 2016

ASTRO Commends Proposed Cancer Research Increases in President’s 2017 Budget

Budget request includes $1 billion for Cancer Moonshot Initiative and 13 percent increase in biomedical research funding at the National Cancer Institute

ASTRO, Fiscal Year 2017 Budget, cancer research, Moonshot Initiative

February 18, 2016 — The American Society for Radiation Oncology (ASTRO) commended the proposed investment in cancer-related research announced in the Fiscal Year 2017 Budget released last week by the White House. ASTRO, whose members include nearly all practicing radiation oncologists in the United States, further encouraged policymakers to increase levels of sustained financial support for research on cancer treatment, detection and prevention as the Cancer Moonshot Initiative matures.

The President’s FY2017 budget includes requests for $5.9 billion to support biomedical research at the National Cancer Institute, an increase of $680 million (13 percent) from FY2016 levels, as well as $1 billion to accelerate progress in cancer treatment and detection through the Cancer Moonshot Initiative.

ASTRO sent a letter to Vice President Joe Biden articulating the multiple reasons it supports the moonshot effort, including a growing need to develop and employ radiation in combination with other therapies for cancer treatment; opportunities to leverage advances in “big data” analytics; and a need to increase access to clinical trials and the latest cancer research.

“Never before have clinicians been able to induce remission in those suffering from cancer like they have today through the use of radiation therapy in combination with other treatment modalities,” wrote ASTRO chair Bruce D. Minsky, M.D., FASTRO, in the letter. “Now is the time for siloed fields to coalesce and synergize to drive progress in leaps rather than in small increments. … To do this, the funding structure must reflect the reality that the most successful treatment will not be a single modality but rather a combination that includes radiation therapy, chemotherapy and surgery.”

For more information: www.astro.org

Related Content

Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...
Feature | Radiology Business | September 07, 2018 | By Marilyn M. Singleton, M.D., J.D.
“Disruptive innovation” is all the buzz. Repealing the Affordable Care Act (ACA) is so last year. Well, disrupt this:...
GlobalData: Amazon Poised to Make Huge Strides in Healthcare
News | Radiology Business | August 31, 2018
A new report from data and analytics company GlobalData suggests that Amazon is poised to make huge strides in...
Non-Canonical Strategy May Improve Cancer Radiotherapy
News | Radiation Therapy | August 29, 2018
August 29, 2018 — Although the success or failure of...
Videos | Treatment Planning | August 28, 2018
A discussion with...
Sponsored Content | Webinar | Radiation Therapy | August 28, 2018
Respiratory tumor motion often complicates the delivery of precision radiation treatment.
Tsuyama Chuo Proton Beam Center Treats First Patients With RayStation
News | Treatment Planning | August 27, 2018
Tsuyama Chuo Hospital in Okayama Prefecture, southwest Japan, has commenced clinical use of RayStation to plan pencil...
Radiation Therapy Affects Event Recall for Children With Brain Tumors
News | Radiation Therapy | August 24, 2018
Children with certain types of brain tumors who undergo radiation treatment are less likely to recall the specifics of...
Overlay Init